News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

March 16, 2022 Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
March 2, 2022 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
February 28, 2022 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
February 22, 2022 Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results
January 3, 2022 Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
December 15, 2021 Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH
December 13, 2021 Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population
November 29, 2021 Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 18, 2021 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
November 16, 2021 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock